New Gram Positive Agents to Treat Acute Bacterial Skin and Skin Structure Infections.
Copyright policy )New Gram Positive Agents to Treat Acute Bacterial Skin and Skin Structure Infections.
The FDA guidance published in 2013 provided requirements for conducting ABSSSI trials. In 2014, dalbavancin, oritavancin, and tedizolid were introduced into the market after phase III noninferiority clinical trials against vancomycin (for the lipoglycopeptides) and linezolid (for tedizolid), demonstrating clinical efficacy for the treatment of ABSSSI. Great interest exists for these agents because of the postulated financial impact. Due to favorable pharmacokinetics which allow for less frequent medication administration and shorter treatment durations, these agents may prove to reduce hospital admissions and length of stay.
Glycopeptides, Lipoglycopeptides, Skin Diseases, Bacterial, Organophosphates, Anti-Bacterial Agents, Treatment Outcome, Clinical Trials, Phase III as Topic, Vancomycin, Practice Guidelines as Topic, Costs and Cost Analysis, Humans, Teicoplanin, Oxazoles
Glycopeptides, Lipoglycopeptides, Skin Diseases, Bacterial, Organophosphates, Anti-Bacterial Agents, Treatment Outcome, Clinical Trials, Phase III as Topic, Vancomycin, Practice Guidelines as Topic, Costs and Cost Analysis, Humans, Teicoplanin, Oxazoles
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).0 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Average
Citations provided by BIP!Popularity provided by BIP!